Amgen Dips On Downgrade Thanks To Obesity Drug

By Investor's Business Daily | Oct 14, 2024 at 10:19 AM EST

Amgen stock dropped due to an analyst's downgrade citing that the potential for its weight-loss drug, MariTide, is already factored into the stock price. The drug activates GLP-1 and GIP hormones differently from competitors. Amgen aims for $5 billion in peak sales.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.